Our programs
The Riboscience library of nucleoside and non-nucleoside molecules is rationally designed to deliver drug candidates that are highly effective and highly selective for essential targets in oncology and virology.
ENPP1 program
RBS2418
Phase 1 clinical trial
ENPP1 expression correlates with immune evasion, a cold tumor phenotype and non-response to cancer treatment with immunotherapy and chemotherapy. Blocking ENPP1 with a specific inhibitor protects the critical immune messenger cGAMP from hydrolysis. As a result, accumulation of cGAMP activates the STING-mediated immune response—which causes immune recognition of the cancer, T-cell infiltration into the tumors, tumor regression and disease control.
Riboscience is developing RBS2418, a potent ENPP1 inhibitor that can be taken orally. It has achieved all its Phase 1 clinical trial goals of excellent safety and tolerability, pharmacokinetics (high compound concentrations in blood and tumors), pharmacodynamics (effective ENPP1 inhibition and immune activation) and significand disease control across a range of different cancer types.
Phase 2 clinical trial (currently enrolling)
Advanced colorectal carcinoma
See the stages of ENPP1 inhibitions at work
Watch a Riboscience nucleoside analog in action as it chemically stops and blocks undesirable viral RNA in its tracks—thereby preventing replication and spread.
Read more about ENPP1
Riboscience ESMO presentation highlights safety, PK, PD, and efficacy data from the first 19 patients of the ENPP1 inhibitor RBS2418 Phase 1 study
First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer
Riboscience ESMO I/O presentations highlight RBS2418 Phase 1 study design and the first human data from the evaluation of an ENPP1 inhibitor for immune activation
Other programs
Virus-stopping strategies for Hepatitis B, Influenza, HPV
In research
All viruses must replicate to survive. Nucleoside analogs block viral replication by mimicking the naturally occurring components of RNA or DNA (A, C, G, and U or T). As nucleoside analogs are incorporated into new viral genomes, they result in defective genomes that are not able to replicate. The nucleoside analogs typically have thousands of chances to compromise any single new given viral genome—stopping virus production in the body.
Our proprietary nucleoside analogs are less toxic and more efficacious than the current standard of care.
Get to know us better
Learn more about what’s happening at Riboscience.
